1 / 30

Larry Norton, M.D. Memorial Sloan-Kettering Cancer Center New York, New York

TAXOL® ( paclitaxel ) for Adjuvant Treatment of Node Positive Breast Cancer Oncologic Drug Advisory Committee Adjuvant Chemotherapy of Breast Cancer. Larry Norton, M.D. Memorial Sloan-Kettering Cancer Center New York, New York. Adjuvant Chemotherapy of Primary Breast Cancer: What We Know.

ostinmannual
Télécharger la présentation

Larry Norton, M.D. Memorial Sloan-Kettering Cancer Center New York, New York

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TAXOL® (paclitaxel) for Adjuvant Treatment of Node Positive Breast CancerOncologic Drug Advisory Committee Adjuvant Chemotherapy of Breast Cancer Larry Norton, M.D. Memorial Sloan-Kettering Cancer Center New York, New York

  2. Adjuvant Chemotherapy of Primary Breast Cancer: What We Know • Chemotherapy Improves Disease-Free and Overall Survival • Polychemotherapy > Monochemotherapy • Multiple Cycles > Single Exposure • No Major Advantage to Durations > 3 Months • Anthracycline Combinations > CMF

  3. Early Breast Cancer Trialists’ Collaborative Group Impact of Prolonged Polychemotherapy On Reducing (in % ± SD) Annual Odds of... Comparison (N) CMF vs. Nil (8,150) CMF+ vs. Nil (3,218) Anthracyclines+ vs. CMF (6,950) Longer vs. Shorter (6,104) Recurrence +24 ± 3 +20 ± 5 +12 ± 4 +7 ± 4 Death +14 ± 4 +15 ± 5 +11 ± 5 -1 ± 5 Lancet Vol. 352, 9/98

  4. Simulation of Impact of Chemotherapy Annual Odds of Recurrence: Nil = 15%/Yr CMF = 11.4%/Yr (Reduced by 24%) AC = 10%/Yr (Reduced by 12%) 100 80 60 % Free of Recurrence 40 AC CMF 20 Nil 0 0 2 4 6 8 10 Years

  5. Adjuvant Chemotherapy of Primary Breast Cancer: What Else We Know • Adriamycin Doses < 40mg/m2 are Inferior to 60 mg/m2 (CALGB 8541) • Cyclophosphamide Doses > 600 mg/m2 are not Superior (NSABP B-22) • Chemotherapy Seems More Effective in ER- Than ER+ Disease (EBCTCG)

  6. Early Breast Cancer Trialists’ Collaborative Group Impact of Prolonged Polychemotherapy On Reducing (in % ± SD) Annual Odds of... Subgroup (N) Age < 50, ER- (1398) Age < 50, ER+ (1115) Age  50, ER- (3240) Age  50, ER+ (6793) Recurrence +40 ± 7 +33 ± 8 +30 ± 5 +18 ± 4 Death +35 ± 9 +20 ± 10 +17 ± 6 +9 ± 5 Lancet Vol. 352, 9/98

  7. Adjuvant Chemotherapy of Primary Breast Cancer: How To Improve • Dose-Escalate Anthracycline? • Integrate New Agents? • Chemotherapy? • Biological Agents? • Improve Drug Scheduling? • Dose-Density, Sequential?

  8. Recently Approved New Drugs for the Treatment of (Advanced) Breast Cancer: • Paclitaxel • Docetaxel • Capecitabine • Trastuzumab

  9. Adjuvant Chemotherapy of Primary Breast Cancer: Why Paclitaxel? • Active as First Chemotherapy for Stage IV: 52-59% Response Rates (M.D. Anderson, MSKCC et al.) • Active after Extensive Prior Chemotherapy, Including Anthracycline-Resistant Disease: 22-30% Response Rates (NCI, MSKCC et al.)

  10. 1012 1010 108 Cell Number 106 104 102 1 0 1 2 3 4 5 6 7 Months A 1&2 “Normal” Dose Intensity & Dose Escalation

  11. 1012 1010 108 Cell Number 106 104 102 1 0 1 2 3 4 5 6 7 Months A 1&2 “Normal” Dose Intensity & Dose Escalation

  12. 1012 1010 108 Cell Number 106 104 102 1 0 1 2 3 4 5 6 7 Months “Normal” Dose Intensity & Increased Dose Density B1&3

  13. 1012 1010 108 Cell Number 106 104 102 1 0 1 2 3 4 5 6 7 Months “Normal” Dose Intensity & Increased Dose Density

  14. 1012 1010 108 Cell Number 106 104 102 1 0 1 2 3 4 5 6 7 Months C4&5 Alternating Therapy is Not Dose Dense

  15. 1012 1010 108 Cell Number 106 104 102 1 0 1 2 3 4 5 6 7 Months Sequential Therapy is Dose Dense 3&6

  16. Stage II Breast Cancer with 4 Involved Axillary Lymph Nodes Doxorubicin CMF Bonadonna et al., JAMA, 1995

  17. Stage II Breast Cancer with >4 Involved Axillary Lymph Nodes % at 10 Years p = .002 Bonadonna et al., JAMA, 1995

  18. Paclitaxel 175 mg/m2 CALGB 9141 (Pilot)Node-Positive Stage II-IIIA (N=172) Cyclophosphamide 2000 mg/m2 + G-CSF Doxorubicin 75 mg/m2 130/145 (89.7%)of Patients Starting Paclitaxel Completed Rx. On Paclitaxel: 25% Grade IV Leukopenia 4% Grade IV Thrombocytopenia Demetri et al., ASCO-1997

  19. Intergroup 0148/CALGB 9344Node-Positive Stage II-IIIA Cyclophosphamide Paclitaxel 175 mg/m2 600 mg/m2 Tamoxifen forHR(+) 60 Randomize Doxorubicin mg/m2 75 No Further Chemotherapy 90 G-CSF

  20. Relationship ofCALGB 9344 (Int 0148)toCurrent U.S.Cooperative Group Trials

  21. Cyclophosphamide Paclitaxel 225 mg/m2 600 mg/m2 Doxorubicin 60 mg/m2 NSABP B-28Node-Positive Stage II-IIIA (Survival) No Further Chemotherapy Concomitant Tamoxifen x 5 Years for HR(+) or Postmenopausal (Age  50)

  22. Intergroup/CALGB 9741 Node-Positive Stage II-IIIA 3-Week Cycles 2-Week Cycles (w/ G-CSF) Doxorubicin (A) 60 mg/m2 Paclitaxel (T) 175 mg/m2 Cyclophosphamide (C) 600 mg/m2

  23. Intergroup/SWOG 4-9 LN+ Trial C T A Randomize STAMP I or STAMP V C A

  24. Intergroup/ECOG Stage II TrialHER2 (-) Paclitaxel Tamoxifen if HR(+) Cyclophosphamide 600 mg/m2 Doxorubicin 60 mg/m2 Docetaxel

  25. Integration of Biological Agent:Trastuzumab (Herceptin)

  26. Etc. NSABP Stage II TrialHER2 (+) Paclitaxel Cyclophosphamide 600 mg/m2 Tamoxifen if HR(+) Doxorubicin 60 mg/m2 Herceptin

  27. Intergroup/NCCTG Stage II TrialHER2 (+) Paclitaxel Tamoxifen if HR(+) Cyclophosphamide 600 mg/m2 52 wks Doxorubicin 60 mg/m2 52 wks Herceptin

  28. CALGB Stage IIIB Trial(HER2+) Cyclophosphamide 600 mg/m2 Paclitaxel 90 mg/m2 Surgery & RT Tamoxifen if HR(+) Doxorubicin 60 mg/m2 Herceptin for a Year or Not Dexrazoxane or Not Herceptin or Not

  29. Summary of Advantagesof This Approach • Integrates Paclitaxel • Active as a Single Agent • Active Post-Anthracycline • Minimizes Incremental Toxicity • Allows Integration of Biological Therapy

More Related